Why is Glenmark Pharma falling/rising?

As of 02-Jul, Glenmark Pharmaceuticals Ltd. is experiencing a price increase, currently at 1,766.30, which reflects a rise of 11.9 or 0.68%. The stock has shown strong performance, gaining 3.17% over the past week and 17.75% over the last month, significantly outperforming the Sensex, which rose by only 0.79% and 2.50% respectively. Additionally, the stock is trading close to its 52-week high, just 3.61% away, and has been on a consecutive gain streak for the last three days, with a total return of 2.77% during this period. Glenmark's strong financial health is underscored by a low Debt to EBITDA ratio of 1.00 times and impressive profit growth of 576.7% in the last quarter, contributing to a favorable valuation compared to its peers.
In the broader market context, Glenmark's performance is notably stronger than the benchmark, as evidenced by its year-to-date return of 9.79% compared to the Sensex's 6.75%. The stock's high institutional ownership at 37.8% suggests confidence from knowledgeable investors, which may bolster its price movement. However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 67.57% against the 5-day average, indicating potential caution among retail investors. Overall, the combination of strong financial results, consistent returns over the past three years, and a favorable market position contribute to the stock's rising price.